MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fphar.2025.1505665

Медицинская библиотека · Frontiers in pharmacology · 2025

Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation.

Huang Yu-Ting, Chen Tzu-Ling, Huang Yun-Lin, Kuo Ching-Hua, Peng Yu-Fong, Tang Sung-Chun, Jeng Jiann-Shing, Huang Chih-Feng, Lin Shin-Yi, Lin Fang-Ju

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

This purpose of this study is to analyze the influence of levetiracetam (LEV) on direct oral anticoagulant (DOAC) exposure and its implications for clinical outcomes.

METHODS

This investigation comprised a retrospective cohort study utilizing the integrated medical database and a prospective observational study conducted in a tertiary hospital. Patients aged >65 years with atrial fibrillation and undergoing DOAC therapy were included and were categorized as LEV users and non-users based on LEV exposure status. In retrospective cohort, clinical outcomes between LEV users and non-users were compared, included ischemic stroke or transient ischemic attack (IS/TIA), systemic thromboembolism (STE) and major bleeding. In prospective cohort, DOAC trough concentration was measured.

RESULTS

The retrospective study included 191 LEV users and 694 matched LEV non-users. The risk of IS/TIA and STE were not significantly different between two groups (hazard ratio [HR], 0.99 [0.51-1.91] and 0.94 [0.49-1.79], respectively). For major bleeding, a non-significant higher risk was observed in the LEV-user group in contrast to the LEV-non-user group (HR 2.65 [0.43, 16.33]). The prospective analysis included 19 LEV users and 76 matched LEV non-users. Low DOAC concentrations were observed in 5.3% of LEV-users and 14.5% of LEV non-users (P = 0.53). High DOAC concentration were observed in 10.5% of LEV-users and 11.8% LEV non-users (P = 0.57). The association between LEV therapy and low or high DOAC concentration was non-significant.

CONCLUSION

Concurrent use of LEV and DOAC did not significantly affect DOAC exposure or clinical outcomes. LEV may be a safe anti-seizure medication for patients receiving DOAC therapy.

Для цитирования: Huang Yu-Ting, Chen Tzu-Ling, Huang Yun-Lin, Kuo Ching-Hua, Peng Yu-Fong, Tang Sung-Chun, Jeng Jiann-Shing, Huang Chih-Feng, Lin Shin-Yi, Lin Fang-Ju. Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation.. Frontiers in pharmacology. 2025. DOI: 10.3389/fphar.2025.1505665.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.